CDX2 is a Drosophila caudal-related homeobox transcription factor that is expressed specifically in the intestine. In mice, ectopic expression of CDX2 in the gastric mucosa gives rise to intestinal metaplasia and in one model, gastric carcinoma. In humans, increased CDX2 expression is associated with gastric intestinal metaplasia and tubular adenocarcinomas. These patterns of expression have shown that CDX2 is important for the initiation of intestinal metaplasia in the gastric mucosa, but the role of CDX2 in established gastric cancer remains unclear. We sought to determine whether CDX2 contributes to tumorigenic potential in established gastric cancer. The CDX2 gene in MKN45 gastric carcinoma cells was disrupted using targeted homologous recombination. The resulting CDX2 À/À cells are essentially identical to their parental cells, with the exception of CDX2 ablation. We found no significant differences in the proliferation of CDX2 À/À cells compared to CDX2
Introduction
Gastric carcinoma is the second most common cause of cancer deaths worldwide. The World Health Organization currently divides gastric carcinomas into four histological subtypes: signet-ring cell carcinoma, tubular adenocarcinoma, papillary adenocarcinoma, and mucinous adenocarcinoma (Fenoglio-Preiser et al., 2000) . The signet-ring cell carcinomas correspond to the diffuse-type carcinomas under the previous Lauren classification system (Lauren, 1965) . Signet-ring cell carcinomas affect younger people, consist of individually infiltrating neoplastic cells that do not form glandular structures, and are not associated with intestinal metaplasia (Sipponen and Marshall, 2000) . The tubular adenocarcinomas correspond to the intestinal-type gastric adenocarcinomas under the previous Lauren classification system. Tubular adenocarcinomas occur at a later age, are almost always associated with Helicobacter pylori, and are thought to progress through generally well-defined, histological stages: from normal mucosa to superficial gastritis, atrophic gastritis, intestinal metaplasia, dysplasia, and finally to adenocarcinoma (Correa, 1992; Yuasa, 2003) . Specifically, environmental and host genetic factors contribute to the transition from normal mucosa to superficial gastritis, then atrophic gastritis (Peek and Blaser, 2002) . As a consequence of the chronic inflammation and regeneration, the gastric mucosa may transdifferentiate into intestinal metaplasia (Correa, 1992) . Subsequent accumulation of genetic changes such as inactivating mutations in tumor suppressors, activation of oncogenes, aberrant methylation, and loss of heterozygosity induce dysplasia followed by tubular adenocarcinoma (Correa and Shiao, 1994; McKenna and Appelman, 2002; Yuasa, 2003; Zheng et al., 2004) . Despite extensive diagnostic and therapeutic efforts, the prognosis for patients with advanced gastric cancer remains poor (Ebert and Malfertheiner, 2002) . A challenge that remains in this disease is detecting stage-specific genetic abnormalities that may aid in early diagnosis or as therapeutic targets.
CDX2 is a Drosophila caudal-related homeobox transcription factor that is important for early differentiation and maintenance of intestinal epithelial cells (Suh and Traber, 1996) . CDX2 is specifically expressed in the small and large intestines, and has been shown to transcriptionally activate genes important for intestinal differentiation, morphology, and growth inhibition, including sucrase isomaltase (SI), lactase, carbonic anhydrase, LI-cadherin, MUC2, p21, and KLF4 (Suh et al., 1994; Freund et al., 1998; Mahatan et al., 1999; Fang et al., 2000; Hinoi et al., 2002; Bai et al., 2003; Yamamoto et al., 2003; Guo et al., 2004b) . The role of CDX2 in colon cancer is complex. Heterozygous CDX2-null mice develop colonic hamartomas, and are at increased risk for adenocarcinomas of the colon as induced by azoxymethan or loss of heterozygosity at the Adenomatous Polyposis Coli locus; which suggested that CDX2 has a tumor suppressor role (Chawengsaksophak et al., 1997; Aoki et al., 2003; Bonhomme et al., 2003) . In contrast, CDX2 has tumorigenic potential in the human colon cancer cells LOVO and SW48 (Dang et al., 2006) , and Cdx2 is the transforming event in a mouse model of acute myeloid leukemia (Rawat et al., 2004) . As detailed below, the potential roles of CDX2 in gastric cancer are also complex.
Several lines of evidence link ectopic activation of CDX2 to the development of intestinal metaplasia. In two separate mouse models, ectopic expression of CDX2 in the stomach induced gastric intestinal metaplasia Silberg et al., 2002) . In humans, CDX2 is not expressed in normal gastric cells but is prominently expressed in gastric intestinal metaplasia, consistent with its putative role in the induction of gastric intestinal metaplasia (Bai et al., 2002; Eda et al., 2002; Satoh et al., 2002; Almeida et al., 2003; Mizoshita et al., 2004b; Tsukamoto et al., 2004) .
The role of CDX2 in the progression and aggressiveness of gastric carcinoma remains more speculative. Of the two CDX2-transgenic mouse models of intestinal metaplasia, only one eventually developed into invasive gastric tubular adenocarcinomas (Mutoh et al., 2004) . In this model, ectopic expression of CDX2 was driven by the parietal cell-specific promoter of the rat b-subunit (Mutoh et al., 2004) . This model directly demonstrated that intestinal metaplasia progressed to malignant and invasive gastric adenocarcinoma. However, whether the continued ectopic gastric expression of CDX2 contributed to the development of gastric cancer remained unclear. In contrast, while ectopic expression of CDX2 driven by the gastric glandular-specific Foxa3 promoter also induced gastric intestinal metaplasia, gastric carcinoma has not been reported (Silberg et al., 2002) . Thus, the role of CDX2 expression in gastric cancer progression and maintenance remains speculative.
As CDX2 is a putative tumor suppressor in colon cancer, its expression is thought to hinder the progression of gastric cancer (Guo et al., 2004b) . In support of this line of speculation, some studies have shown that CDX2 is more abundantly expressed in well-differentiated tumors and cell lines, which may be associated with an improved prognosis (Bai et al., 2002; Seno et al., 2002; Mizoshita et al., 2003) . These association studies suggested that as cancer cells became less differentiated during progression, CDX2 became downregulated. Thus, in theory, re-expression of CDX2 may induce differentiation and growth arrest (Yuasa, 2003; Yuasa et al., 2005) . However, other studies have reported that even though CDX2 is expressed in tubular adenocarcinomas, adjoining intestinal metaplasia, as well as tubular adenocarcinoma cell lines, its expression is independent of differentiation status Kaimaktchiev et al., 2004; Mizoshita et al., 2004a, b) . Thus, although multiple studies have associated CDX2 expression with tubular adenocarcinomas, the direct effect of CDX2 on established gastric cancer, the stage at which it is commonly diagnosed, has not been elucidated. A clearer understanding of how CDX2 may contribute to tumorigenicity in gastric cancer cells may optimize its utilization as a prognostic factor, or even as a therapeutic target (Seno et al., 2002; Zheng et al., 2004) . In this paper, we report the consequences of genetic disruption of CDX2 in the human gastric adenocarcinoma cell line MKN45 by targeted homologous recombination.
Results

Expression and genetic analysis of CDX2
The MKN45 gastric adenocarcinoma cell line was established from the tumor of a 62-year-old Japanese patient with undifferentiated gastric cancer (Motoyama et al., 1986) . Ultrastructurally, the derived cell line had features of gastric mucosa and intestinal metaplastic mucosa, with considerable development of microvilli, desmosomes, and interdigitations (Motoyama et al., 1986) . Consistent with their being tubular in origin, tumors generated from MKN45 cells were found to form tubular structures with lumen, within which mucus and microvilli were detected (Motoyama et al., 1986; Kobayashi et al., 1999) . Over the years, multiple studies have supported that MKN45 cells can be categorized as a tubular adenocarcinoma. In a recent comprehensive analysis of gene expression profiles in human gastric cancer cell lines, MKN45 was clustered with gastric cell lines that were derived from tumors that progressed from intestinal metaplasia (Ji et al., 2002) . Specifically, these cell lines highly expressed villin and LI-cadherin, which had been shown to be expressed in gastric mucosa with intestinal metaplasia (Osborn et al., 1988; Grotzinger et al., 2001) . Concomitantly, MKN45 cells express b-catenin, parathyroid hormone-related peptide, and furin, consistent with tubular adenocarcinomas (Ebert et al., , 2003 Nakajima et al., 2002) . Finally, two factors associated with intestinal metaplasia and tubular adenocarcinomas are expressed in MKN45 cells: intestinal trefoil factor (ITF) and CDX2. ITF is expressed mainly in the goblet cells of the small and large intestines. Increased ITF expression has been associated with intestinal metaplasia in normal subjects, tubular adenocarcinomas, and in MKN45 cells .
Previous studies have shown that CDX2 is transcriptionally expressed in MKN45 cells. In a comparison study between normal gastric epithelium and 11 human gastric cancer cell lines, MKN45 was found to express moderate amounts of CDX2 by reverse transcription (RT)-PCR analyses (Bai et al., 2000) . In the same study, the expression of GATA 4/5 transcription factors was associated with CDX2 expression in MKN45 cells. GATA 4/5 is important for intestinal epithelial cell differentiation and has previously been reported to be regulated by CDX2 (Gao et al., 1998; Boudreau et al., 2002) . In another study, CDX2 was shown to transcriptionally regulate the intestine-specific gene MUC2 in MKN45 cells, in a similar manner as in colon cancer cells (Mesquita et al., 2003) . These data again support that MKN45 cells are derived from a tubular adenocarcinoma, express CDX2, and have an intact CDX2 transcription machinery. However, the biological function of CDX2 in MKN45 cells remains unclear.
We examined the expression of CDX2 in human cancer cell lines and tissues by real-time RT-PCR ( Figure 1a ). Consistent with published reports (Bai et al., 2000) , CDX2 was minimally expressed in normal human stomach, upregulated in stomach cancer tissue, and moderately expressed in MKN45 cells. Thus, the level of CDX2 expression in MKN45 cells is comparable to levels seen in gastric cancer tissues, other gastric cancer cell lines, and some colon cancer cell lines.
As mutations in CDX2 have been reported in colorectal cancer, we sequenced the three exons, exon-intron boundaries, and complete coding region of CDX2 in MKN45 cells (Figure 1b) . We found that CDX2 was not mutated. Thus, wild-type CDX2 is moderately expressed in MKN45 gastric cancer cells.
Genetic disruption of CDX2 by targeted homologous recombination Human somatic cell gene knockout provides a model to directly study gene function within a specific human cancer cell type (Sikorski and Peters, 1997; Sedivy et al., 1999; Bunz, 2002; Waldman, 2004) . The gene of interest is targeted for disruption through homologous recombination. The resulting cells are essentially identical to the parental cells, except for genetic inactivation of the specific gene. When somatic knockouts are utilized in cancer cells, gene function can be precisely elucidated within a myriad of background mutations (Bunz, 2002) . This investigative approach has provided important insights into the functions of genes relevant to colon cancer such as K-ras, p53, p21, and b-catenin (Shirasawa et al., 1993; Waldman et al., 1995; Brown et al., 1997; Bunz et al., 1998 Bunz et al., , 1999 Chan et al., 1999 Chan et al., , 2002 Kim et al., 2002 Kim et al., , 2004 .
Cancer cell knockouts have been generated predominantly in colorectal cancer cells and have not been reported in gastric cancer cell lines or the CDX2 gene. We disrupted CDX2 in MKN45 gastric carcinoma cells by targeted homologous recombination. We reasoned that it was important to target the disruption in MKN45 gastric cancer cells rather than colon cancer cells, as CDX2 functions in a cell type-specific manner. Furthermore, the level of CDX2 expression may affect its function, and CDX2 expression in MKN45 cells is most consistent with levels found in primary gastric cancers and cell lines (Bai et al., 2000) (Figure 1a ). Finally, MKN45 cells have been shown to be near diploid, stable over long periods in culture, and consistent with a tubular adenocarcinoma histology (Motoyama et al., 1986) .
We targeted exon 1 of CDX2 for disruption as previously described (Figure 2a ) Cummins et al., 2004a, b; Kohli et al., 2004; Dang et al., 2005 Dang et al., , 2006 . Homozygous disruption of CDX2 was identified by genomic PCR (Figure 2b ). Loss of CDX2 , are essentially identical to their parental MKN45 (CDX2 þ / þ ) clones, with the exception of ablated CDX2 expression. To our knowledge, these cells represent the only set of human gastric cancer cells that differ solely in the presence or the complete absence of endogenous CDX2.
In vitro cell growth and gene expression analyses To determine the effects of CDX2 on growth, we measured cell proliferation through three independent in vitro assays: colorimetric MTS assay, anchoragedependent plating efficiency, and anchorage-independent colony formation. The MTS assay measures the absorbance of formazan, which is proportional to the number of metabolically active cells. We found no significant differences in absorbance over a period of 1 week, indicating no significant differences in cell viability in vitro ( Figure 3a ). We next examined plating efficiency and found that CDX2 À/À cells had B15% advantage in plating efficiency compared to CDX2 þ / þ cells, which was not statistically significant ( Figure 3b and c). These results are consistent with the CDX2 protein's role as a putative tumor suppressor. However, although CDX2 À/À cells tended to form more numerous colonies than CDX2 þ / þ cells, we noted that the colonies were smaller, with decreased numbers of cells and decreased compaction (Figure 3d ). These results are consistent with previous findings in colorectal cancer, in which overexpression of CDX2 in HT29 and colo205 cells increased cell compaction (Mallo et al., 1998; Hinoi et al., 2003; Keller et al., 2004; Dang et al., 2005b) . Thus, loss of CDX2 enhanced the formation of anchorage-dependent colonies that were less compact. We next examined colony formation in semi-solid agar to determine anchorage-independent growth. We found that CDX2 À/À cells formed B20% more colonies than CDX2 þ / þ cells, which was not statistically significant ( Figure 3e ). However, the colonies formed by CDX2 À/À cells were B38% smaller than the colonies formed by 
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( Figure 3e and f). To confirm that CDX2 þ / þ cells were expressing CDX2 under anchorage-independent conditions, we measured CDX2 and LI-cadherin expression. As expected, CDX2 was expressed under anchorage-independent conditions (Figure 3g ). Furthermore, expression of the CDX2-regulated protein LIcadherin was appropriately decreased in CDX2 À/À cells (Hinoi et al., 2002) . Altogether, our data show that loss of CDX2 does not significantly alter MKN45 cell viability or proliferation in vitro. However, loss of To determine whether loss of CDX2 affected cell cycling in MKN45 gastric cancer cells, we performed flow cytometry on cells stained with propidium iodide. We found no significant differences in the percentage of cells in G 0 /G 1 , S, G 2 /M, and sub-G 1 , indicating no differences in cell cycle progression, exit, or apoptosis (Figure 4a ). The proteins p21 and cyclin D1 are important for cell cycle regulation and have been reported to be regulated by CDX2 in colorectal cancer Guo et al., 2004a) . As such, we examined their expression in the two cell lines. We found no significant differences in p21 or cyclin D1 expression in CDX2
þ / þ and CDX2 À/À cells (Figure 4b ). Our data thus support the conclusion that CDX2 does not alter cell cycle progression in MKN45 gastric cancer cells.
CDX2 is a transcription factor that regulates downstream genes important for differentiation. Intestinal cell differentiation occurs through the generation of columnar and mucous progenitors from a pluripotent stem cell (Bjerknes and Cheng, 1999) . The columnar progenitors eventually give rise to enterocytes, whereas the mucous progenitors give rise to secretory cells such as Paneth, goblet, and endocrine cells . We next examined expression of intestinal lineage markers for goblet cells and enterocytes, as these have been extensively associated with CDX2.
We began by determining how CDX2 might affect the expression of genes important for the development of secretory goblet cells. Gastrointestinal-specific mucins are heavily glycosylated glycoproteins that are the major components of the mucous viscous gel covering epithelial cells. The expression of mucins is associated with tissue-specific glands. In particular, MUC2 is specific to intestinal goblet cells (Velcich et al., 2002; Sonoda et al., 2004) . Previous studies have shown that CDX2 transcriptionally regulates the MUC2 gene in MKN45 gastric cancer cells (Mesquita et al., 2003; Yamamoto et al., 2003; Ishikawa et al., 2004) . We found that loss of CDX2 resulted in loss of MUC2 transcripts, consistent with the notion that CDX2 is important for maintenance of MUC2 expression (Figure 4c ). Concomitantly, we found that loss of CDX2 led to increased MUC5AC, which is specific to gastric surface mucous cells (Tsukashita et al., 2001; Niwa et al., 2005) . These findings suggest that CDX2 regulates the expression of MUC2, which is associated with terminal differentiation of goblet cells and an intestinal mucous phenotype. In contrast, CDX2 negatively regulates MUC5AC, which is associated with a gastric surface mucous phenotype. 
Microvillus brush border enzymes are specifically expressed in enterocytes. We examined the expression of brush border enzymes previously shown to be regulated by CDX2: SI, lactase, alkaline phosphatase, and carbonic anhydrase (Suh et al., 1994; Taylor et al., 1997; Fang et al., 2000; Boudreau et al., 2002) . We found that SI, intestine alkaline phosphatase, and carbonic anhydrase were not expressed in CDX2 þ / þ or CDX2 À/À cells (Figure 4c ). We did find that lactase is expressed in MKN45 cells and as such, loss of CDX2 abrogated lactase expression (Figure 4c ). These results show that MKN45 cells express low or no endogenous levels of brush border enzymes. Thus, loss of CDX2 can only minimally alter the expression of brush border enzymes. These data are reminiscent of the Foxa3/Cdx2-transgenic mice, in which the predominant intestinal cell type found in the transdifferentiated gastric mucosa were goblet cells and solely alkaline phosphataseexpressing enterocytes (Silberg et al., 2002) . It is possible that MKN45 cells do not express other factors that cooperate with CDX2 to induce mature enterocytes. Alternatively, MKN45 cells may have transdifferentiated toward the mucous progenitor pathway and thus express only factors sufficient for the differentiation of goblet cells and lactase-expressing enterocytes.
LI-cadherins are mediators of cell-cell adhesion and differentiation that are specifically expressed in the human and mouse intestines. CDX2 has been shown to regulate LI-cadherin gene expression in normal, metaplastic, and neoplastic tissues of the gastrointestinal tract (Hinoi et al., 2002) . As such, we found that loss of CDX2 led to decreased LI-cadherin expression under anchorage-dependent ( Figure 4c ) and anchorage-independent conditions (Figure 3g ). Thus, consistent with the literature, loss of CDX2 in MKN45 gastric cancer cells led to decreased LI-cadherin expression.
Villin is a structural protein that contributes to the formation of microvilli in the small bowel. Although villin is not expressed in the stomach, it is expressed in the intestine, specifically the apical surface of absorptive enterocytes, as well as goblet cells (Cheng and Leblond, 1974; Boller et al., 1988; Friederich et al., 1990; Pinto et al., 1999) . We found that despite having limited expression of brush border enzymes, MKN45 cells did express villin. Furthermore, loss of CDX2 resulted in increased villin expression (Figure 4c ). These findings have two implications. First, the MKN45 cell line has properties of a tubular adenocarcinoma. Second, villin may be negatively regulated by CDX2 in MKN45 cells, or alternatively increased expression of villin may be a compensatory response to loss of CDX2.
Kru¨ppel-like factor 4 (KLF4) is a zinc-finger-containing transcription factor, which, like CDX2, is expressed in the post-mitotic cells of the intestinal epithelium (Shields et al., 1996) . KLF4 has been shown to mediate cell cycle arrest by activation of p21 (Zhang et al., 2000) . In addition, KLF4 is a putative target gene of CDX2 (Mahatan et al., 1999; Dang et al., 2001 ). As such, KLF4 has been shown to regulate similar genes as CDX2, for example p21 and MUC2 (Katz et al., 2002; Yoon et al., 2003) . In mice, KLF4 is required for goblet cell formation in the colon (Katz et al., 2002) . We found that loss of CDX2 in MKN45 cells resulted in increased KLF4 gene expression (Figure 4c ). These findings suggest that KLF4 may be negatively regulated by CDX2 in this cell line, or alternatively increased expression of KLF4 may be a compensatory response to loss of CDX2.
Altogether, the molecular data show that loss of CDX2 in MKN45 cells resulted in (1) decreased expression of genes expressed in terminally differentiated glandular intestinal cells, for example MUC2; (2) decreased expression of endogenous brush border enzymes such as lactase; (3) decreased expression of the adhesion mediator LI-cadherin; and (4) increased expression of genes that regulate glandular and enterocyte differentiation, for example KLF4 and villin. These molecular profiles suggest that loss of CDX2 results in decreased expression of a set of terminal differentiation genes and increased expression of a set of more upstream differentiation regulators.
At the cellular level, loss of CDX2 resulted in (1) no significant alterations in cell proliferation or cell cycle progression and (2) decreased compaction of cell colonies. These cellular alterations corresponded with a trend toward increased numbers, but decreased sizes of anchorage-independent colonies.
In vivo xenograft growth and differentiation analyses
To determine how the in vitro molecular and cellular changes translated to in vivo gastric tumor growth, we proceeded to implant athymic nude mice with CDX2 þ / þ and CDX2 À/À cells. After 2 weeks of growth in vivo, we found no significant differences in xenograft volumes ( Figure 5a ). As seen by Western blot analyses, CDX2 expression persisted in the CDX2 þ / þ xenografts in vivo, and loss of CDX2 was again associated with decreased LI-cadherin expression (Figure 5b ). Further examination of the tumor xenografts by hematoxylin and eosin revealed sheets of poorly differentiated carcinoma, consistent with the previously described tumor phenotype (Figure 5c ). Staining with Ki-67 for proliferation revealed similar degrees of proliferation in both types of xenografts (Figure 5c ). To examine for differences in gross differentiation, we stained the xenografts with Alcian blue pH 2.5, which stains for glycosaminoglycans such as acetic mucins that are found in goblet cells. We found that both groups of xenografts formed rare luminal structures (Figure 5c ). Thus, there were no significant alterations in microscopic tumor differentiation.
As CDX2 is known to function in a contextdependent fashion, we examined two additional models of in vivo tumorigenesis: the orthotopic and the intraperitoneal models. The orthotopic model was utilized to determine whether CDX2 expression altered MKN45 tumor growth in situ. We proceeded to implant
, and CDX2 À/À cells orthotopically into the gastric walls of nude mice. We observed a statistically insignificant trend that mice harboring CDX2 þ / þ tumors had increased incidences of nodules in the omentum and stomach when compared to mice harboring CDX2 þ /À and CDX2 À/À tumors (Figure 5d ). Conversely, mice with CDX2 À/À tumors had an increased incidence of mesenteric nodules. The quantities and sizes of nodules were similar when present. Thus, CDX2 did not appear to alter MKN45 tumor CDX2 does not suppress tumorigenicity in MKN45 cells LH Dang et al growth in situ. The intraperitoneal model was utilized to determine whether CDX2 expression altered peritoneal carcinomatosis. Peritoneal carcinomatosis is a common manifestation of gastric cancer, and is associated with poor survival. We proceeded to implant
, and CDX2 À/À cells into the intraperitoneal cavities of nude mice and recorded their ensuing survival. We found no significant differences in survival (Figure 5e ). At necropsy, we noted that tumors had engrafted in all mice. All tumors, irrespective of CDX2 status, formed one large omental mass and multiple mesenteric and peritoneal nodules. Altogether, our results show that loss of CDX2 in MKN45 cells does not significantly alter tumorigenicity in vivo.
Discussion
In summary, we have shown that in MKN45 gastric cancer cells, (1) targeted homologous recombination is feasible, (2) loss of CDX2 leads to altered gene expression at the molecular level, (3) loss of CDX2 leads to a trend of increased anchorage-dependent growth, (4) loss of CDX2 decreases colony compaction and cellularity, and (5), loss of CDX2 does not significantly alter in vivo tumorigenicity. To our knowledge, these are the first studies to determine directly the functional contribution of CDX2 to gastric tumor microscopic morphology and tumorigenicity.
The biological role of CDX2 in established gastric cancer had been hypothesized to inhibit proliferation and induce differentiation. Our findings do not support that CDX2 is a tumor suppressor in MKN45 cells. In the CDX2
À/À cells, it is possible that the positive growth kinetics associated with increased plating efficiency and colony numbers were opposed by the negative growth kinetics associated with decreased compaction and colony size. Consequently, the CDX2 À/À cells had no obvious alterations in proliferation or cell cycling. Alternatively, perhaps the level of CDX2 expression in MKN45 cells is not sufficiently high enough to affect tumorigenicity. However, MKN45 cells are one of the high CDX2-expressing gastric cancer cell lines (Bai et al., 2000 (Bai et al., , 2002 . Thus, the levels of CDX2 in MKN45 cells are consistent with endogenous levels in gastric cancers. As such, these data suggest that moderate endogenous expression of CDX2 does not significantly affect tumorigenic potential in tubular adenocarcinomas.
In the same vein, CDX2 does not appear to grossly affect MKN45 gastric cancer differentiation. Although loss of CDX2 led to molecular and cellular alterations, loss of CDX2 did not alter the histology of tumor xenografts. A potential explanation for these observations is that MKN45 cells are too undifferentiated to de-differentiate further. However, it is notable that activation of the enzyme phosphatidylinositol 3-kinase can de-differentiate MKN45 cells, yielding xenografts with markedly decreased lumens (Kobayashi et al., 1999) . Alternatively, the MKN45 cell line may be glandular in origin, and CDX2 may have a greater contribution to a cell line with a more mature enterocyte lineage. Finally, our molecular data would suggest that other genes such as KLF4 and villin might be upregulated in a compensatory manner, thus obviating the deficits in cellular differentiation and proliferation that may have been induced by the loss of CDX2.
We conclude that CDX2 is not a tumor suppressor in the MKN45 gastric tubular adenocarcinoma cell line. Combining the results of previous studies in CDX2-transgenic mice and this study, it would appear that although CDX2 is important for the formation of intestinal metaplasia in the stomach, its continuous expression might not affect the progression and maintenance of tubular adenocarcinomas. Thus, CDX2 is unlikely a tumor suppressor in established tubular adenocarcinomas of the stomach. As such, there have been no reports of loss of heterozygosity of CDX2 in human gastric cancers.
Materials and methods
Cell culture and tissues LS174T, HCT116, SW480, RKO, HT29, and Hep3B cells were acquired from the American Type Culture Collection (Manassas, VA, USA). MKN45 and MKN74 cells were acquired from the Japanese Collection of Research Bioresources/ Human Science Research Resources Bank (Osaka, Japan). Cell lines were maintained in recommended media supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Total RNA from human tissues was acquired from BD Biosciences Clontech (Palo Alto, CA, USA).
Sequencing
To ensure accuracy, CDX2 was sequenced from two sources: genomic DNA and cDNA (Figure 1b) . Three primer sets were used to amplify the three CDX2 exons and exon-intron boundaries from genomic DNA (NM_001265): exon 1 primers: 5 0 -CTCTGCAGCCTAGTGGGAAG-3 0 (forward) and 5 0 -TCACTCCCAGGCTCAGTAGG-3 0 (reverse); exon 2 primers: 5 0 -GGGTGGTGGAGGAAGAGAA-3 0 (forward) and 5 0 -CCAAAGACGAATGCTTGCAT-3 0 (reverse); and exon 3 primers: 5 0 -ATGCCCGAGGAAAGCTTCTA-3 0 (forward) and 5 0 -TGCTCTGGGGTAAAATGAGG-3 0 (reverse). In addition, total RNA was extracted from cells, reverse transcribed, and the B1 kb coding region of CDX2 amplified to generate cDNA using the primers 5 0 -GCCACCATG TACGTGAGCTA-3 0 (forward) and 5 0 -CTCAGCCTG GAATTGCTCTG-3 0 (reverse) (NC_000013). All products were sequenced by the University of Michigan Sequencing Core Facility. Sequences were aligned using the BL2SEQ program from the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov).
Real-time RT-PCR analyses
Total RNA was extracted and treated with DNase I. Singlestranded cDNA was generated using MMLV reverse transcriptase (Bio-Rad, Hercules, CA, USA). Real-time PCR reactions were performed in triplicate on derived cDNA using SYBRGreen Supermix (Bio-Rad). CP (crossing point at which fluorescence rises appreciably above the background fluorescence) was averaged, and relative expression was calculated using the formula, ratio ¼ 2 À½CP experimental ÀCP GAPDH (Pfaffl, 2001 ). PCR products met three criteria to be included in the study: (1) the signals from the RT-derived cDNA were at least 100-fold greater than that of control reactions performed without RT, (2) PCR products from the reactions with RT were of the expected size on gel electrophoresis, and (3) melt curves analyses were consistent with specificity of PCR. Primers used were as follows: CDX2, 5 0 -CAGCCATGGGC TACAGCAG-3 0 (forward) and 5 0 -GTTGAGCGTTTGCAG CAG-3 0 (reverse); GAPDH, 5 0 -AAAGGGCCCTGACA ACTCTT-3 0 (forward) and 5 0 -GGTGGTCCAGGGGTCT TACT-3 0 (reverse); MUC 2 (NM_002457), 5 0 -ACTACCAC TGCGATCCCAAC-3 0 (forward) and 5 0 -GCATCATATG CACGGTCTTG-3 0 (reverse); MUC5AC (AF_043909), 5 0 -CT CCGAATCCAGCTACAAGC-3 0 (forward) and 5 0 -TGGTC CTCAGAGATGGGAAG-3 0 (reverse); KLF4 (NM_004235), 5 0 -ACCCTGGGTCTTGAGGAAGT-3 0 (forward) and 5 0 -GCAGGAAGGATGGGTAATTG-3 0 (reverse). Primers for villin, sucrase isomaltase, carbonic anhydrase, lactase, LI-cadherin, and intestinal alkaline phosphatase were previously described (Keller et al., 2004) .
Western blot analyses
Whole-cell proteins were extracted and separated by electrophoresis. After transfer to nitrocellulose membranes, blots were probed with primary and horseradish peroxidase-coupled secondary antibodies, and visualized by chemiluminescence reagent (Perkin-Elmer, Norton, OH, USA). At the end of the experiment, membranes were stripped and re-probed for a-tubulin to confirm equal loading. Antibodies were obtained from Biogenex Inc. (San Ramon, CA, USA; mouse anti-human CDX2), Cell Signaling Technologies (Beverly, MA, USA; cyclin D1, p21), Sigma (St Louis, MO, USA; a-tubulin), Santa Cruz Biotechnology (Santa Cruz, CA, USA; LI-cadherin), and Transduction Labs (San Diego, CA, USA; villin). Antibody dilutions were as recommended by the manufacturers.
Targeted disruption of CDX2 by homologous recombination
The endogenous CDX2 locus, AAV knockout construct, and resulting targeted locus are shown in Figure 1c . The strategy is as previously described Cummins et al., 2004a, b; Kohli et al., 2004; Dang et al., 2005 Dang et al., , 2006 . Exon 1 of CDX2 was targeted for disruption with an AAV cassette containing the Neomycin resistance gene (Neo) under the constitutive control of an SV40 promoter flanked by left and right homology arms approximately 1 kb in length (Figure 2a) . Successful disruption resulted in a 250 bp deletion and translation stop codons in all three reading frames. Cells exhibiting neomycin resistance were screened with locusspecific PCR using primers specific for exon 1 (Figure 2b ). Once the first allele was successfully targeted, the Neo was excised using Cre recombinase (Microbix Biosystems Inc., Toronto, Canada). The same targeting vector was then used to target the second allele. Loss of CDX2 was confirmed by Western blot analyses (Figure 2c ).
Cell proliferation and colony formation assays
For cell proliferation assays, cells were plated into 96-well plates and MTS added as per the manufacturer's recommendations (Promega CellTiter 96 Assay, Madison, WI, USA). The measurement of absorbance of the formazan was carried out at 492 nm. As the production of formazan is proportional to the number of living cells, the intensity of the produced color is an indication of viability of the cells. For analyses of colony formation on culture plates, 1.0 Â 10 4 cells were plated into each well of a six-well plate and allowed to grow for 2 weeks. Colonies of cells were stained with 0.1% crystal violet and the total number of colonies per well was counted using Image Pro Plus software for Windows (www.mediacy.com). For anchorage-independent growth assays, 2.0 Â 10 4 cells per well were suspended in 0.33% agar and plated on six-well plates layered with 0.5% agar. Cells were allowed to grow for 2 weeks and spherical colonies were photographed at Â 20 and quantitated using Image Pro Plus software.
The over-agar cell culture method The over-agar cell culture method enables ready recovery of cells growing in anchorage-independent conditions. Cell culture plates were layered with 0.5% agar in complete growth medium. Cells were trypsinized, gently dispersed, and plated in complete media on top of the agar (Dong and Cmarik, 2002) . For cell recovery, the liquid growth medium and unattached cells were transferred to a conical tube, centrifuged, and the cells recovered.
Cell cycle analyses
For cell cycle analyses, cells were permeated with 70% ice-cold ethanol and stained with 50 mg/ml propidium iodide in PBS containing 0.2% Tween 20 and 2.5 mg/ml RNase. DNA content was measured on a FACSCalibur Cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) and data were analysed using Modfit Lt software (Verity Software House, Topsham, ME, USA).
In vivo tumorigenesis
For xenograft studies, CDX2 þ / þ and CDX2 À/À cells (5.0 Â 10 6 ) were harvested and implanted subcutaneously into the flanks of 6-week-old female athymic nu/nu mice (Charles River Labs, Wilmington, MA, USA). Tumor sizes in two dimensions were measured and volumes were calculated using the formula (LW 2 ) Â 0.5, where L is length and W is width. Mice were euthanized once overwhelmed by tumor burden and the tumor xenografts harvested for imaging. Means and standard deviations of tumor volumes were calculated and plotted. Two-tailed Student's t-test was used to determine statistical significance between groups.
For orthotopic implantation studies, CDX2 þ / þ , CDX2 þ /À , and CDX2 À/À (10 Â 10 6 ) cells were implanted into the gastric wall of 6-week-old female athymic nu/nu mice (Sakate et al., 2004) . At the end of 6 weeks, mice were euthanized and necropsy performed. The percent of mice harboring nodules in the stomach, mesentery, omentum, and anterior peritoneum were tallied.
For peritoneal carcinomatosis studies, CDX2 þ / þ , CDX2 þ /À , and CDX2 À/À (25 Â 10 6 ) cells were implanted intraperitoneally into 6-week-old female athymic nu/nu mice (Piso et al., 2003) . Time to death was recorded and a Kaplan-Meier survival curve generated as previously described (Dang et al., 2004) . All animal protocols were approved by the University of Michigan Animal Care and Use Committee. Mice were housed in barrier environments, with food and water provided ad libitum. Mice were euthanized as per published guidelines (Ullman-Cullere and Foltz, 1999).
Immunohistochemistry
Harvested tumors were fixed in formalin, paraffin embedded, and serial sections obtained. For staining, slides were deparaffinized in xylene, rehydrated, and stained with hematoxylin and eosin, ki-67, and Alcian blue pH 2.5 by the University of Michigan tissue core facility. Stained sections were examined independently by an experienced pathologist (HDA) who was blinded to tumor identifiers. Images were captured by Spot Software on an Olympus BX41 microscope at Â 100 and Â 400 magnifications.
Statistical analyses
In vitro experiments were performed in triplicate and repeated twice. In vivo experiments were repeated once. Results are expressed as means7standard deviation of all experiments. Two-tailed Student's t-test was used to determine whether the differences noted between cell lines were statistically significant (Po0.05). For Kaplan-Meier curves, the w 2 statistic was used to determine whether the three survival curves were significantly different.
